News >

Ibrutinib Highly Active Against MCL in Pooled Analysis

Jason Harris
Published: Tuesday, Sep 19, 2017

Simon Rule, MD
Simon Rule, MD, PhD
In a pooled analysis of 370 patients, investigators determined that ibrutinib (Imbruvica) induced an objective response rate (ORR) of 66% in patients with mantle cell lymphoma (MCL), according to results published in the British Journal of Haematology.

The incidence of other malignancies was 5.7% in the overall population, most of which (67%) were nonmelanoma skin cancers.
Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies (published online August 18, 2017). Br J Haematol. doi: 10.1111/bjh.14870.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x